Iron deficiency potentially causes thrombocytosis (increase in platelets in blood) and that can result in thrombotic complications (clots). Treatment with Intravenous iron therapy can fix that quick rather than oral iron.
Impact of anemia and acute coronary syndromes is getting more and more described.
In my opinion, CSL is trying to get foothold in cardiology and nephrology divisions, expanding from its predominant blood product/vaccine pipeline.
Iron deficiency potentially causes thrombocytosis (increase in...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$288.93 |
Change
0.320(0.11%) |
Mkt cap ! $139.9B | |||
| Open | High | Low | Value | Volume |
| $287.64 | $289.70 | $287.16 | $174.5M | 601.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 149 | $288.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $288.96 | 1858 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |